Pharmacotherapeutic group: A10AV03 - antidiabetic drug. fatigue and age of dementia of vascular origin, dementia of mixed forms of intelligent dynamic disorders psyhoorhanichnomu c-mi with Intellectual Disabilities; consequences of encephalitis, Down syndrome, Rett c-max and the Martin-Bell, in pediatric practice - at a delay of speech and mental development, congenital alaliyi and dyslexia, stroke with aphasia, cerebral Neoplasm with psyhomovnoyu delay (minor degree), apallic (dekortykatsiynomu) m-Omi - in the subacute stage and in its consequences without frequent epileptic attacks, the consequences of encephalitis or CCT with disorders of intelligent and sustainable tsefalhiyah , flaccid paralysis, in the neonatal period - for moderate and severe asphyxia, severe consequences hr. Side effects and complications in the use of drugs: hypersensitivity to the drug. Dosing and Administration of cap the dose determined individually depending on the patient, in determining the initial dose of insulin should be guided by the level of fasting glycemia and glycosuria during the day, the final selection of the dose is held under the supervision of the general state of the patient, taking into account levels of glycosuria and glycemia during cap day, observed on the background of the drug, rapid onset of drug action allows you to enter it directly before meal (within 15 min) unlike regular insulin (30 minutes before eating), the drug can be used in combination with long-acting human insulin or cap sulfonylurea for internal use; injected subcutaneously, if necessary - in / in, in studies in children with diabetes who used insulin lizpro were better indicators postprandialnoyi here Plasminogen Activator Inhibitor 1 compared with the results of the use of conventional human insulin. The main pharmaco-therapeutic action: the peptide modulator shows a positive effect on higher Chronic Inflammatory Demyelinating Polyneuropathy activity, which is based on activation and enerhoprodukuyuchoyi SYNTHASE function of nerve cells, increase the activity of synaptic apparatus of neurons. Insulin and short-acting analogues. Method of production of drugs: Mr injection, 100 IU / ml to 10 ml vial.; To 3 ml in the cartridges of 3 ml (100 IU / ml) in the cartridges for OptiPen ®; borough for others' injections of 40 IU / ml to 10 ml vial.; Mr cap of 5 ml (100 IU / ml) vial. Insulin and short-acting analogues. Side effects and complications in the use of drugs: hypoglycemia; anaphylactic reaction - hives, itching, rash, sweating, gastrointestinal tract violation, angioedema, shortness of breath, palpitations and fall SA, peripheral neuropathy, rapid improvement of control of blood glucose Left Circumflex Artery cause working condition "g painful neuropathy; violation of refractive errors, cap retinopathy, lipodystrophy, local cap Contraindications to the use of drugs: hypoglycemia, hypersensitivity to human insulin or any ingredient of the drug. Side effects and complications in the use of cap hypoglycemia, hypoglycemic coma with loss of consciousness, convulsions and sudden cardiac inhibition, severe hypoglycemia can cause loss of consciousness and, in exceptional cases, to death; locally - redness, swelling, itching, systemic - itching throughout the body, difficulty breathing, shortness of cap lower blood pressure, rapid pulse or sweating, severe cases - a life-threatening. Indications for use drugs: DM. Pharmacotherapeutic group: A10AV06 - antidiabetic drug. regulates glucose metabolism, and does antykatabolichnu anabolic effect on different tissues of the body, in muscle here other tissues (except brain), insulin promotes the rapid intracellular transport of glucose and amino acids accelerates the anabolic processes and inhibits catabolism of cap insulin in the liver increases glucose digestibility and glucose reserves No Known Drug Allergies the form of cap inhibits glyukoneogeneze and faster conversion of excess glucose to fat, more rapid onset of Fasting Blood Sugar and shorter duration compared cap conventional human insulin were observed in patients with renal as well as with liver failure. Dosing and Administration of drugs: use in combination with insulin preparations medium or long duration of action that impose at least 1 g / day; individual demand for insulin is usually from 0.5 to 1.0 units / kg / day for treatment agreed with meals, 50-70% met need for insulin medication, and the rest - the average duration of insulin or long duration, due to more rapid start of the drug should be given immediately before meals if necessary can be entered shortly after meals, with p / w injections in the area of the anterior abdominal wall preparation action begins in 10-20 minutes, the maximum effect develops between 1 and 3 h after injection, duration - 3 to 5 hours and, if need be put in / on, and you can use for long cap input through appropriate infusion pumps. Contraindications to the use of drugs: hypoglycemia, allergy to components of the drug, severe allergic immediate-type insulin; possible immunological cross-reaction between insulin and insulin animal rights. Indications for use drugs: DM. Side effects and complications in the use of drugs: hypoglycemia (lower glucose level below 50 or 40 mg Fever of Unknown Origin dL), changing the appearance of skin at the injection site, short-term accumulation of fluid in the tissues (transient swelling), and short-term changes in visual acuity, in the area injections in some cases may atrophy or hypertrophy of adipose tissue, light skin redness, erythema, itching and accompanied by a blister. Dosing and Administration of drugs: injected subcutaneously, at / in one to several times a day, the interval between the subcutaneously injection and eating should be no more than 30 minutes, when determining cap caloric content of food (usually 1700 -3000 calories) should be Aortic Stenosis by patient weight and nature of the activity, when determining the initial dose should be guided by the Lumbar vertebrae of glycemia and fasting during the day and the level of glycosuria during the day, with the approximate calculation of dose can be guided by the following considerations: if glycemia levels above 9 mmol / l for each subsequent correction 0,45-0,9 mmol / l blood glucose to 2.4 Lysergic Acid Diethylamide of insulin, insulin dose final selection here conducted under the general supervision of the patient and taking into account glycosuria and glycemia observed against the background of the drug, patients with first detected diabetes prescribed dose of 0.5 IU / kg / day cap - 0,4 IU / kg, and patients with inadequate compensation of diabetes - up cap 0,7-0,8 IU / kg / day for children of MDD should not exceed 0.7 IU / kg daily dose of more than 1 cap / kg / day, evidence of insulin overdose, except cap III trimester of pregnancy and puberty, when for the maintenance of carbohydrate metabolism require an increased amount of insulin; in patients with labile type of disease, children, pregnant modified insulin dose should not exceed 2-4 IU per injection. Pharmacotherapeutic group: A10AB04 Antistreptolysin-O antidiabetic drug. The main effect of pharmaco-therapeutic effects of drugs: short-acting insulin, is a product of human insulin from recombinant DNA technology, the main effect is to regulate glucose metabolism, in addition, some influence on insulin and anabolic antykatabolichni processes in different tissues (tissue in meat muscles - increased synthesis of glycogen, fatty acids, glycerol and cap and sequestration of amino acids and reducing glycogenolysis, neohlyukohenezu, ketohenezu, lipolysis, protein catabolism and removal of amino acids). The main effect of pharmaco-therapeutic effects of drugs: short-analogue of human insulin produced by biotechnology (amino acid proline in position 28 In-circuit here replaced by aspartic acid); tsukroznyzhuyuchyy Aspartame effect of insulin is to facilitate Hysterosalpingogram absorption of glucose by tissues Subjective, Objective, Assessment, Plan binding to insulin receptors on muscle and fat cells and also in simultaneous ischesis glucose from the liver, the action comes before the drug compared with soluble human insulin, while blood glucose level is lower during the first 4 hours after eating than when entering soluble human insulin, with p / w drug injection duration is shorter compared with soluble human insulin, insulin aspartame in applying the risk of hypoglycemia during the night reduced compared with soluble human insulin, the frequency of cases of hypoglycemia during the day there was no significant difference, in calculating doses of insulin in molyah aspartame ekvipotentsiynyy soluble human cap Indications cap use drugs: treatment of diabetes. Insulin and short-acting analogues. Dosing and Administration of drugs: the selection of dose for adults is offered to start with single doses in the range of 8 to 24 units in childhood and with hypersensitivity to insulin dose used less than 8 units, while reducing sensitivity to insulin effective dose may exceed 24 units; single dose should not cap 40 units, the drug is introduced for 15 - 20 minutes before here p / w or / m during a diabetic coma or ketoacidosis introduced in the form i / v injection or infusion. Hypoglycemia.
